English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The ability of the topical spot-on Advantix ®  (50 % permethrin/10 % imidacloprid) to prevent transmission of  Ehrlichia canis  by infected  Rhipicephalus sanguineus  ticks to dogs has previously been reported. The recent market introduction of chewable tablets containing the novel compounds, afoxolaner (NexGard™) and fluralaner (Bravecto™) enabled us to conduct a comparative efficacy study with respect to the ability of these three products to block transmission of  E. canis  by ticks to dogs. The speed of kill, immediate drop-off rate and anti-attachment efficacy of the respective products were also studied.    Methods  The study was a blinded parallel group design, wherein 32 dogs were randomised into four different groups of eight dogs. Group 1 served as negative placebo control, group 2 and 3 were treated on Days 0, 28 and 56 with NexGard™ and Advantix ® , respectively. Group 4 was dosed once on Day 0 with Bravecto™. For tick efficacy assessments 50 non-infected ticks were placed onto the dogs on Days 30, 35, 42, 49, 56, 63, 70, 77 and 84 and on animal tick counts were performed at 3 h, 6 h and 12 h after infestation. To evaluate the ability to block transmission of  E. canis , each dog was challenged by releasing 80 adult  E. canis -infected  R. sanguineus  ticks into their sleeping kennels on Days 31, 38, 45 and 52. The animals were monitored for clinical signs of monocytic ehrlichiosis (pyrexia and thrombocytopenia) and were tested for  E. canis  DNA by PCR and for specific antibodies using IFA. A dog was considered infected with  E. canis  if both PCR and IFA yielded positive test results up to Day 84.    Results  Mean arithmetic tick counts on dogs treated with the Advantix ®  spot-on were significantly ( P  < 0.0005) lower throughout the study as compared with the negative controls and was, with respect to the speed of kill and resulting onset of acaricidal efficacy, superior over NexGard™ and Bravecto™ at all time points in the 12 h period observed (3 h, 6 h and 12 h). None of the dogs treated with the Advantix ®  spot-on became infected with  E. canis , whereas six out of eight untreated control dogs acquired the infection. Furthermore,  E. canis  infection was diagnosed in four out of eight dogs treated with NexGard™ and in two out of eight dogs treated with Bravecto™.    Conclusions  The speed of kill of the two recently registered systemic compounds against  R. sanguineus  was not sufficiently fast to prevent transmission of  E. canis  and resulted in only low partial blocking and protection capacity while Advantix ®  effectively blocked transmission of  E. canis  to dogs in the challenge period and thus provided adequate protection for dogs against monocytic ehrlichiosis.

parasites and vectors

Comparative efficacy of oral administrated afoxolaner (NexGard™) and fluralaner (Bravecto™) with topically applied permethrin/imidacloprid (Advantix®) against transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs